An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

被引：0
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Kim, Dong-Wook [2 ]
Kantarjian, Hagop M. [3 ]
Brummendorf, Tim H. [4 ,5 ,11 ]
Dyagil, Irina [6 ]
Griskevicius, Laimonas [7 ]
Malhotra, Hemant [8 ]
Goh, Yeow-Tee [9 ]
Wang, Junyuan [10 ]
Gogat, Karin [10 ]
Cortes, Jorge [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Seoul St Marys Hosp, Seoul, South Korea
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[5] Univ Klinikum Aachen, Hamburg, Germany
[6] Ukraine Acad Med Sci, Res Ctr Radiat Med, Kiev, Ukraine
[7] Vilnius Univ Hosp, Santarigkio Klin, Vilnius, Lithuania
[8] SMS Med Coll & Hosp, Birla Canc Ctr, Jaipur, Rajasthan, India
[9] Singapore Gen Hosp, Singapore 0316, Singapore
[10] Pfizer Inc, Cambridge, MA USA
[11] Univ Klinikum Aachen, Aachen, Germany
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [31] A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia
    Samal, Priyanka
    Chakrabarti, Prantar
    Nath, Uttam K.
    INDIAN JOURNAL OF CANCER, 2019, 56 (03) : 211 - 215
  • [32] Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia
    Garrett, May
    Knight, Beverly
    Cortes, Jorge E.
    Deininger, Michael W.
    CANCER MEDICINE, 2023, 12 (17): : 17981 - 17992
  • [33] Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial
    Brummendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Hochhaus, Andreas
    Lipton, Jeff H.
    Kota, Vamsi
    Deininger, Michael W.
    Leip, Eric
    Viqueira, Andrea
    Ferdinand, Roxanne
    Cortes, Jorge E.
    BLOOD, 2018, 132
  • [34] Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study
    Ono, Takaaki
    Hino, Masayuki
    Matsumura, Itaru
    Fujisawa, Shin
    Ishizawa, Kenichi
    Sakaida, Emiko
    Sekiguchi, Naohiro
    Ono, Chiho
    Aizawa, Mana
    Tanetsugu, Yusuke
    Koide, Yuichiro
    Takahashi, Naoto
    BLOOD, 2021, 138
  • [35] Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan
    Tadashi Nagai
    Jin Takeuchi
    Nobuaki Dobashi
    Yuzuru Kanakura
    Shuichi Taniguchi
    Koji Ezaki
    Chiaki Nakaseko
    Akira Hiraoka
    Masaya Okada
    Yasushi Miyazaki
    Toshiko Motoji
    Masaaki Higashihara
    Norifumi Tsukamoto
    Hitoshi Kiyoi
    Shinji Nakao
    Katsuji Shinagawa
    Ryuzo Ohno
    Tomoki Naoe
    Kazunori Ohnishi
    Noriko Usui
    International Journal of Hematology, 2010, 92 : 111 - 117
  • [36] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Deininger, Michael W.
    Mauro, Michael J.
    Chuah, Charles
    Kim, Dong-Wook
    Dyagil, Irina
    Glushko, Nataliia
    Milojkovic, Dragana
    le Coutre, Philipp
    Garcia-Gutierrez, Valentin
    Reilly, Laurence
    Jeynes-Ellis, Allison
    Leip, Eric
    Bardy-Bouxin, Nathalie
    Hochhaus, Andreas
    Brummendorf, Tim H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 231 - +
  • [37] Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan
    Nagai, Tadashi
    Takeuchi, Jin
    Dobashi, Nobuaki
    Kanakura, Yuzuru
    Taniguchi, Shuichi
    Ezaki, Koji
    Nakaseko, Chiaki
    Hiraoka, Akira
    Okada, Masaya
    Miyazaki, Yasushi
    Motoji, Toshiko
    Higashihara, Masaaki
    Tsukamoto, Norifumi
    Kiyoi, Hitoshi
    Nakao, Shinji
    Shinagawa, Katsuji
    Ohno, Ryuzo
    Naoe, Tomoki
    Ohnishi, Kazunori
    Usui, Noriko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 111 - 117
  • [38] Health-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinib-resistant (IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloid leukemia (CP CML).
    Trask, P. C.
    Cella, D.
    Besson, N.
    Kelly, V.
    Masszi, T.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Chen, Suning
    Zhang, Yanli
    Xu, Na
    Sun, Hui
    Li Weiming
    Yang, Yunfan
    Zhu, Zunmin
    Duan, Minghui
    Qian, Sixuan
    Zhu, Yu
    Luo, Jianmin
    Wang, Xiaodong
    Yang, Wei
    Gu, Weiying
    Li, Fei
    Liu, Bingcheng
    Xu, Yunxiao
    Liu, Zhenfang
    Wang, Chunling
    Jiang, Yirong
    Meng, Li
    Wen, Qin
    Xu, Yanli
    Zou, Xingli
    Wang, Wei
    Xue, Yan
    Xu, Hao
    Bi, Kehong
    Zhou, Fuling
    Ma, Liangming
    Fu, Rong
    Ouyang, Guifang
    Ding, Kaiyang
    Wu, Depei
    BLOOD, 2023, 142
  • [40] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
    Saglio, Giuseppe
    Kim, Dong-Wook
    Issaragrisil, Surapol
    le Coutre, Philipp
    Etienne, Gabriel
    Lobo, Clarisse
    Pasquini, Ricardo
    Clark, Richard E.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Gallagher, Neil
    Hoenekopp, Albert
    Dong, Mei
    Haque, Ariful
    Larson, Richard A.
    Kantarjian, Hagop M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2251 - 2259
12345